ExpreS2ion Biotech Holding AB (EXPRS2) AI Stock Analysis

• Market Cap: €56.06M
• Dividend Yield: N/A
• Average Volume (3M): 19.88K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.24
• Revenue Growth: 8.46%
• EPS Growth: 11.73%
• Country: SE
• Employees: 20
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -3.18
• Shares Outstanding: 3,530,233
• 10 Day Avg. Volume: 26,629
• 30 Day Avg. Volume: 19,883
• PEG Ratio: 0.01
• Price to Book (P/B): 0.54
• Price to Sales (P/S): 11.56
• P/FCF Ratio: -1.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: kr16.00 ▼(-2.44% Downside)

The overall stock score is primarily influenced by the company's poor financial performance and weak technical indicators. The negative P/E ratio and lack of dividend yield further contribute to the low valuation score. The absence of earnings call data and notable corporate events leaves these areas unaddressed.

Positive Factors

Proprietary Platform

The proprietary ExpreS2 platform provides a competitive advantage by offering a unique solution for antibody production, supporting long-term growth through licensing and partnerships.

Strategic Partnerships

Strategic partnerships enhance revenue potential and resource availability, supporting sustainable growth and innovation in biopharmaceutical applications.

Low Debt Levels

Low debt levels provide financial stability and flexibility, allowing the company to invest in growth opportunities without significant financial strain.

Negative Factors

Consistent Net Losses

Persistent net losses highlight operational inefficiencies and pose a risk to long-term financial sustainability, potentially limiting future investments in growth.

Negative Cash Flow

Negative cash flow limits the company's ability to fund operations and growth initiatives internally, potentially leading to increased reliance on external financing.

Decline in Revenue

A decline in revenue indicates potential market challenges or competitive pressures, affecting the company's ability to maintain growth and profitability.

ExpreS2ion Biotech Holding AB Business Overview & Revenue Model

Company Description

ExpreS2ion Biotech Holding AB (EXPRS2) is a biotechnology company specializing in the development of innovative solutions for antibody production and other biopharmaceutical applications. The company operates primarily in the life sciences sector, focusing on its proprietary ExpreS2 platform, which enables rapid and cost-effective production of high-quality proteins and antibodies. ExpreS2ion aims to support pharmaceutical companies and research institutions in their efforts to develop novel therapies, particularly in the areas of cancer and infectious diseases.

How the Company Makes Money

ExpreS2ion Biotech generates revenue primarily through its proprietary ExpreS2 platform, which is licensed to pharmaceutical and biotech companies for the production of antibodies and proteins. The company earns money from licensing agreements, where clients pay fees for using the ExpreS2 technology, as well as milestone payments and royalties based on the commercial success of products developed using its platform. Additionally, ExpreS2ion may engage in collaborative agreements with strategic partners that can provide funding and shared resources for research and development projects, further enhancing its revenue potential.

ExpreS2ion Biotech Holding AB Financial Statement Overview

Summary

ExpreS2ion Biotech Holding AB is facing financial challenges with consistent net losses and negative cash flow. While the company has a stable equity position and low debt levels, its inability to generate positive income and cash flow highlights operational inefficiencies and potential risks.

Income Statement

The company has experienced a decline in total revenue from 2023 to 2024, with a significant net loss, indicating poor profitability. The gross profit margin is negative due to higher costs than revenues. While revenue growth was positive from 2022 to 2023, it declined sharply from 2023 to 2024.

Balance Sheet

The equity ratio is moderate, reflecting a balanced but somewhat leveraged position. The debt-to-equity ratio is low, indicating limited reliance on debt. However, the return on equity is negative, showing inefficiency in generating profits from equity.

Cash Flow

The company has negative free cash flow, indicating challenges in generating cash from operations after capital expenditures. The operating cash flow to net income ratio is negative, showing cash inefficiency, despite a decrease in negative free cash flow from 2023 to 2024.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.82M	3.01M	7.05M	5.09M	12.23M	5.26M
Gross Profit	-8.18M	-2.67M	3.40M	5.00K	4.72M	-843.00K
EBITDA	-51.61M	-64.34M	-102.45M	-124.49M	-46.38M	-28.47M
Net Income	-45.55M	-36.04M	-91.40M	-118.61M	-43.92M	-31.71M
Balance Sheet
Total Assets	61.77M	104.53M	78.69M	137.36M	151.96M	118.86M
Cash, Cash Equivalents and Short-Term Investments	36.88M	81.54M	57.60M	110.97M	138.88M	106.83M
Total Debt	1.51M	1.80M	1.71M	1.85M	2.11M	2.38M
Total Liabilities	28.47M	40.11M	13.33M	34.04M	11.61M	24.31M
Stockholders Equity	33.29M	64.80M	65.36M	103.33M	140.35M	94.55M
Cash Flow
Free Cash Flow	-47.08M	-34.80M	-102.90M	-100.00M	-46.36M	-19.06M
Operating Cash Flow	-47.08M	-33.93M	-100.89M	-99.61M	-45.65M	-18.18M
Investing Cash Flow	43.00K	21.27M	-2.02M	105.33M	-100.92M	-1.08M
Financing Cash Flow	9.15M	34.87M	47.84M	61.46M	74.55M	123.38M

ExpreS2ion Biotech Holding AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 16.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:EXPRS2, the sentiment is Negative. The current price of 16.4 is below the 20-day moving average (MA) of 17.04, below the 50-day MA of 18.20, and below the 200-day MA of 21.55, indicating a bearish trend. The MACD of -0.73 indicates Positive momentum. The RSI at 40.18 is Neutral, neither overbought nor oversold. The STOCH value of 24.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:EXPRS2.

ExpreS2ion Biotech Holding AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LARK	52 Neutral	€50.49M	-1.13	―	8.20%	-94.12%	-25.83%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
EXPRS2	41 Neutral	€56.06M	―	-88.65%	―	8.46%	11.73%
ONCOZ	41 Neutral	kr77.02M	―	-78.79%	―	―	20.55%
SPRINT	39 Underperform	€158.27M	―	-264.12%	―	-17.80%	-11.96%
ACOU	39 Underperform	€58.62M	-3.24	-80.90%	―	59.70%	44.60%
STABL	34 Underperform	kr16.32M	―	-91.33%	―	―	64.02%